biz.yahoo.com
Thursday March 16, 8:24 am Eastern Time
Company Press Release
SOURCE: Genome Therapeutics Corp.
Genome Therapeutics Files Registration Statement For Public Offering
WALTHAM, Mass., March 16 /PRNewswire/ -- Genome Therapeutics Corp. (Nasdaq: GENE - news) today announced that it is has filed a Registration Statement with the Securities and Exchange Commission in connection with its proposed public offering of 3,000,000 shares of Common Stock.
CIBC World Markets will serve as lead managing underwriter and Warburg Dillon Read, Dain Rauscher Wessels and Tucker Anthony Cleary Gull will serve as co-managing underwriters for the proposed offering. The Company has also granted the underwriters an option to purchase an additional 450,000 shares to cover any over-allotments, if any.
Copies of the prospectus relating to the offering, when available, may be obtained from CIBC World Markets, 200 Liberty Street, New York, NY 10281, or by faxing a request to 212.667.5730.
A Registration Statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Genome Therapeutics (www.genomecorp.com) is a leader in the commercialization of genomics-based drug discovery. The Company's gene discovery strategy is to identify and characterize human genes associated with major diseases and elucidate microbial genes as novel drug targets against many serious infectious organisms. Together with its strategic partners, including Schering-Plough, AstraZeneca, Wyeth-Ayerst and bioMerieux, Genome Therapeutics is using genomic information to develop a new generation of genomics-based pharmaceutical, vaccine and diagnostic products.
Statements in this press release that are not strictly historical are ``forward looking' statements as defined in the Private Securities Litigation Reform Act of 1995. A number of important factors could cause actual results to differ materially from those projected or suggested in the forward looking statement including, but not limited to, the ability of the Company and its alliance partners to (i) successfully develop products based on the Company's genomic information, (ii) obtain the necessary governmental approvals, (iii) effectively commercialize any products developed before its competitors and (iv) obtain and enforce intellectual property rights, as well as the risk factors described in the Company's Annual Report on Form 10-K. |
